SHAKUNTALA JAIN: Open Payments
NPI 1629157771 · PHOENIX, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$769 in 33 payments from 11 companies in 2025. Trend: 2023 $186 · 2024 $440 · 2025 $769
Food & beverage: $769
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 8 | $164 |
| Neurocrine BioSciences, Inc. | 4 | $123 |
| Otsuka America Pharmaceutical, Inc. | 3 | $78 |
| Alkermes, Inc. | 3 | $76 |
| Vanda Pharmaceuticals Inc. | 2 | $74 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $64 |
| ABBVIE INC. | 3 | $62 |
| E.R. Squibb & Sons, L.L.C. | 3 | $53 |
| Janssen Pharmaceuticals, Inc | 2 | $46 |
| Luye Pharma (USA) Ltd. | 1 | $14 |
Products named: INGREZZA, AUSTEDO XR, UZEDY, FANAPT, REXULTI, CAPLYTA, VRAYLAR, COBENFY.
Industry payments across AZ — which companies pay providers there.
